Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG2 with Chemoradiation for Locally Advanced Esophageal Cancer
NCT03611712Phase 2Completed
- Sponsor
- PhytoHealth Corporation
- Start
- Feb 2019
- Primary completion
- Feb 2023
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of astragalus polysaccharides in esophageal cancer (2 arms), sponsored by PhytoHealth Corporation. Primary endpoint: Fatigue by the Brief Fatigue Inventory-Taiwanese Form (BFI-T) at 12 weeks. Started Feb 2019; status: completed.
02
Drugs
astragalus polysaccharides
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03611712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611712.